MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
globenewswire.com
·

Type 1 Diabetes Market Size is Estimated to Reach US$ 13.64

The Type 1 Diabetes Market, valued at US$ 7.59 billion in 2022, is projected to grow to US$ 13.64 billion by 2030, with a CAGR of 7.6%. Treatment involves external insulin support, primarily through parenteral administration. The market is competitive, with major players investing in R&D for effective treatments. Key segments include devices, end-users, and products.
finance.yahoo.com
·

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript

Syros Pharmaceuticals reported a Q1 2023 EPS of $-0.85, beating expectations of $-1.09. The company highlighted progress in clinical trials for MDS, AML, and APL, including the SELECT-MDS-1 trial's amendment to include overall survival as a key secondary endpoint. Syros anticipates pivotal data from SELECT-MDS-1 in Q3 2024 and remains on track for milestones across its programs. Financials show a net loss of $23.8M, with $166M in cash, expected to fund operations into 2025.
finance.yahoo.com
·

OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up

OPKO Health's ModeX Therapeutics partners with Merck to develop MDX-2201, a nanoparticle vaccine targeting Epstein-Barr virus (EBV). OPKO receives $50M upfront, with potential milestone payments and royalties. The collaboration leverages Merck's expertise to combat EBV, linked to mononucleosis and certain cancers, aiming to enhance OPKO's pharmaceutical business globally.
yahoo.com
·

NOT REAL NEWS: A look at what didn't happen this week

Misinformation debunked: Claims about NIH nominee's Pfizer grants, a soldier aiding illegal border crossings, Biden touching a child inappropriately, and the polio vaccine causing cancer are false. Each claim was fact-checked and corrected by the Associated Press, revealing manipulated images, misrepresented facts, and outdated information.
pmlive.com
·

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Novavax starts phase 2 trial for COVID-19/influenza and stand-alone influenza vaccines, targeting adults 50-80. Initial results expected mid-year, informing phase 3 trials. Aims to offer better protection, especially for older adults, and explore combining COVID-19 and influenza protection. Pfizer/BioNTech also testing mRNA-based combination vaccine.
drughunter.com
·

The Molecular Glue Degrader Landscape in 2022

The article highlights Drug Hunter's selection of Molecules of the Month, focusing on compounds targeting SOS1, NLRP3, SMARCA2, and more. It discusses CNS project challenges, the E-sol metric for predicting CNS exposure, and DEL technology's role in drug discovery. Also, it mentions notable molecules like Maze’s GYS1 inhibitors and allosteric AR modulators.
finance.yahoo.com
·

Clinical Trials Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The clinical trials market, valued at USD 39,710.28 million in 2021, is projected to reach USD 52,711.08 million by 2027, growing at a CAGR of 5.05%. Factors driving growth include increased R&D spending, the impact of COVID-19, aging populations, and the rise in chronic diseases. North America leads in market growth due to high R&D expenditure and the prevalence of diseases.
kffhealthnews.org
·

The Business of Clinical Trials Is Booming. Private Equity Firms Invest Billions to Expedite Drug Approvals and Increase Profits

Private equity firms are investing billions in clinical drug trials, aiming to expedite drug approvals and increase profits. Companies like Headlands Research, backed by KKR, focus on enhancing trial efficiency and diversity. Despite challenges, including staffing and site closures, the clinical trials industry has grown, attracting significant private equity interest due to its profitability and lower risk compared to direct drug company investments.
investopedia.com
·

Top Biotech Stocks for Q2 2023

Viking Therapeutics, Biomea Fusion, and Ardelyx Inc. reported significant stock price increases following positive clinical trial results and sales forecasts. Biotech stocks offer high rewards and acquisition potential but face risks like failure and regulatory hurdles, exemplified by BioNTech's success and Zosano Pharma's bankruptcy.
brookings.edu
·

Early claims and M&A behavior following enactment of the Inflation Reduction Act

The biopharmaceutical industry fears the Inflation Reduction Act's drug price negotiation could harm R&D investments. Despite concerns, major firms report increased R&D spending and optimistic future earnings. M&A activity remains strong, with a focus on small molecule drugs and treatments for older adults, showing little impact from the IRA.
© Copyright 2025. All Rights Reserved by MedPath